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went allogeneic HCT in SGH between January 2005 and
December 2010, with at least one year follow-up, was carried
out for the pre-implementation phase. Patients who under-
went allogeneic and autologous HCT between May 2012 and
February 2013, with at least six months follow-up were
reviewed for the post-implementation phase. Primary
endpoint was the overall vaccination rate. Secondary end-
points included the time to ﬁrst vaccination and infection
rate.
Results: Eighty-one evaluable patients were included in the
pre-implementation phase, of whom, 41 did not receive any
vaccination. In the post-implementation phase, among the
39 evaluable patients, only 9 did not receive any vaccination.
Among those vaccinated, median time to ﬁrst vaccination
was 20 (range, 4-72) months post-HCT in the pre-imple-
mentation phase versus 6 (range, 4-13) months post-HCT in
the post-implementation phase. Overall vaccination rate at
various time-points was 3.4% and 59.3% for the pre- and
post-implementation group, respectively (p<0.05). Inﬂuenza
infection occurred in 18 (22.2%) patients pre-implementa-
tion as compared to 3 (7.7%) post-implementation. Of note,
these infections occurred in patients who did not receive
inﬂuenza vaccine.
Conclusions: The vaccination chart detailing the required
vaccines at various time-points post-HCT proved to be a
useful aid in facilitating timely prescribing and accurate
tracking of vaccination status. Timely administration of
required vaccines may result in reduced infectious compli-
cations. Importance of more effective strategies to further
improve vaccination rates in this high risk population is
underscored.458
Plerixafor Mobilization in MM Patients and Impact on
CD34 Cell Collection and Transplant Outcomes
Ali McBride 1, Susan Geyer 2, Samantha Jaglowski 3,
Steven M. Devine 4, Leslie A. Andritsos 5. 1 The University of
Arizona Cancer Center, TUCSON, AZ; 2 Division of Biostatistics,
The Ohio State University, Columbus, OH; 3Division of
Hematology, Ohio State University Medical Center, Columbus,
OH; 4 James Cancer Center, Ohio State Medical Center,
Columbus, OH; 5Division of Hematology, The Ohio State
University, Columbus, OH
Background: Plerixafor (Mozobil) has been approved for use
in multiple myeloma (MM) and non-Hodgkin lymphoma
(NHL) patients (pts) in combination with G-CSF to mobilize
hematopoetic stem cells (CD34) in collection for autologous
transplant (tx). Many different mobilization approaches exist
in this ﬁeld, and we evaluate the role of Plerixafor in MM and
amyloidosis (AL) pts.
Methods: To evaluate plerixafor mobilization in the trans-
plant setting, all MM and AL patients whoweremobilized for
autologous stem cell transplant (autoSCT) between 2010 and
2012 were included. Sufﬁcient CD34+ cell collection was
deﬁned both using a minimal cutpoint of 2x106 as well as an
optimal goal of 5x106 CD34 cells. Signiﬁcant inﬂuences on
the ability to achieve these collection goals on day 1 and
across all collections were evaluated using univariate logistic
regression models in addition to graphical analyses and two
sample tests. In addition to clinical characteristics, weassessed the impact of plerixafor mobilization use and also
lenalidomide and thalidomide use on these outcomes.
Results: Overall, 196 pts (10 AL, 182 MM, 4 MM/AL) were
mobilized for autoSCTs from 2010-2012. Most pts were male
(60%), most were Caucasian (88%), and the median age at
transplant was 59 years (range: 18 to 73). About half of pts
(52%) received lenalidomide (lena), and only 5% received
thalidomide prior to mobilization; the median number of
lena cycles was 4 (range: 1 to 11). Comorbidity indices were
similar to those who did vs. did not receive plerixafor
(p¼0.8). On day 1 collections, 154 pts achieved a yield of
>2x106 and 87 pts>5x106 CD34+ cells. Across all collections,
all but 2 pts had a total yield of at least 2 million CD34 cells,
and 152 had at least 5x106 CD34 cells. Several factors
appeared to inﬂuence a pts ability to achieve a yield of
>5x106 CD34+ cells: age (OR¼0.94, p¼0.014), day 1 yield of
>2x106 CD34+ cells (OR¼14.5, p<0.0001), and the total
number of collections (OR¼0.32, p<0.0001). Days to ANC
recovery after transplant was also borderline associated with
a total yield of at least 5x106 CD34+ cells (OR¼0.82,
p¼0.075). While lena use was not signiﬁcantly associated
with total yield of 5 million CD34+ cells, pts who had prior
lenawere less likely to achieve a yield of at least 2x106 CD34+
cells on day 1 collection vs. those who did not (OR¼0.48,
p¼0.045). Prior radiation therapy was not signiﬁcantly
associated with any of the collection goal metrics. Plerixafor
use was not signiﬁcantly associated with the ability to ach-
ieve a yield of 5x106 CD34+ cells on day 1 or in total; how-
ever, plerixafor use was signiﬁcantly associated with not
achieving a day 1 collection of at least 2x106 CD34+ cells
(OR¼0.24, p¼0.0007); however, this is likely due more to the
decision algorithms used to determine administration of
plerixafor for mobilization prior to autoSCT than a statement
on the effectiveness of plerixafor as a mobilizing agent.459
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Background: Melphalan at a dose of 200 mg/m2 IV (MEL
200) is considered the standard preparative regimen for
autologous hematopoietic stem cell transplantation (auto-
HCT) for multiple myeloma. However, reduced doses of
melphalan such as140 mg/m2 IV (MEL 140) are often used in
older patients or patients with renal dysfunction.
Methods: The purpose of this retrospective analysis was to
determine if there was a difference in toxicity, treatment-
related mortality (TRM), response rate, progression- free
survival (PFS) or overall survival (OS) in patients that
received 140 mg/m2 of melphalan (MEL 140) compared to
those receiving MEL 200 for auto-HCT. From June 1, 1996
through December 31, 2012, 63 patients received MEL 140.
We compared their outcomes with 252 patients that
received MEL 200.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S286eS296S294Results: Patients in the MEL 140 group were older (median
age 71 vs. 62; P<0.0001), had a higher median b2 micro-
globulin (b2M) level both at diagnosis (5.5 vs. 3.7; p¼0.0002)
and auto-HCT (4 vs. 2.5; p<0.0001), and had a higher median
serum creatinine (Cr) at auto-HCT (1.3 vs. 1.05; p¼0.05). A
higher proportion of patients in MEL 140 were older than 65
with serum Cr> 2mg/dL. Therewas no signiﬁcant difference
in disease status or high-risk cytogenetics between the 2
groups. NCI CTCv3 > grade III non-hematologic toxicity was
not signiﬁcantly different between MEL 140 and MEL 200.
TRM at 100 days and at 1 year was 0% and 0.4% in MEL 140
and 200 (p¼1.0), respectively. Complete remission (CR) rates
in MEL 140 and MEL 200 were 16% and 29%, respectively
(p¼0.03). There was no signiﬁcant difference in (CR) + very
good partial remission (VGPR), or overall response (CR +
VGPR + PR) between MEL 140 and MEL 200. Median follow
up in surviving patients in MEL 140 and 200 was 7.6 and 25
months, respectively. Fifteen (24%) and 64 (25%) patients
died in MEL 140 and MEL 200 groups, respectively, with
>90% of deaths due to recurrent disease. Median PFS was
26.4 and 30.6 months in MEL 140 and MEL 200 groups,
respectively (p¼0.46). Median OS was 38.4 and 93.0 months
in MEL 140 and MEL 200 groups, respectively (p¼0.02).
However, there was no signiﬁcant difference in median PFS
(26 vs. 24.4 months) or median OS (38.6 vs. 62.2 months) in
patients older than 65 between MEL 140 and MEL 200.
Similarly, there was no signiﬁcant difference in median PFS
(24.5 vs. 31.3 months) or median OS (32.1 months vs. 69.3
months) in patients with a serum Cr > 2 mg/d between MEL
140 and MEL 200.
Conclusion: The dose of melphalan can be safely reduced to
140 mg/m2 in patients >65 or with renal insufﬁciency
without adversely impacting the overall response rate or PFS.460
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Background: Rituximab and inﬂiximab are two monoclonal
antibodies administered intravenously. Both medications are
generally administered over prolonged infusion times per
manufacturer guidelines in order to avoid infusion-related
toxicities. Rituximab is a chimeric anti-CD20 monoclonal
antibody used primarily for the treatment of EBV viremia,
autoimmune cytopenias and steroid refractory graft versus
host disease (srGVHD) in hematopoietic stem cell transplant
patients (HSCT) at Cincinnati Children’s Hospital Medical
Center (CCHMC). Recommended infusion times for ritux-
imab average 5-6 hours for the initial dose and 3-4 hours for
subsequent doses. Inﬂiximab is an anti-TNFa monoclonal
antibody used for srGVHD in HSCT patients at CCHMC. Rec-
ommended infusion of inﬂiximab is over 2-3 hours. Due to
the these infusion times, administration of both medications
is associated with decreased patient satisfaction, increased
health care costs and can also lead to compatibility/access
issues. Data exists to support rapid infusion (RI) adminis-
tration (over 1 hour) of these agents in non-HSCT adult pa-
tients, but data in pediatric HSCT patients is limited. Here wedescribe our experience with 1-hour infusions of rituximab
and inﬂiximab at CCHMC.
Methods: All HSCT patients who received rituximab or
inﬂiximab between March 2013 and October 2013 were
administered their ﬁrst dose by the standard manufacturer
guidelines. If patients tolerated the ﬁrst infusion they were
eligible to receive infusion of subsequent doses over 1 hour.
Patients were observed for infusion related reactions during
and for 30 minutes after infusion. Additionally, patients and
family members were advised to report any possible re-
actions within the 24 hours following infusion.
Results: Seven patients received 24 RI rituximab doses. The
median number of doses per patient was 3; (range 1-7). Five
patients were on corticosteroids as part of their baseline
regimen, no patients (including those not on baseline ste-
roids) received additional steroid pre-medication prior to
infusion. No adverse effects were reported with the RI of
rituximab. A total of 49 doses of RI inﬂiximab were admin-
istered to 8 patients. All 8 patients were on corticosteroids as
part of their daily regimen and no one received additional
steroid as pre-medication prior to their infusion. The median
number of inﬂiximab RIs per patient was 7.5 (range 1-17
doses). One patient receiving RI inﬂiximab experienced a
rash that resolved without intervention during the ﬁrst RI.
The patient received 4 additional RIs without side effects. No
additional side effects were seen in any other patients.
Conclusion: Rapid-infusions of rituximab and inﬂiximab
were safe and well tolerated when administered as the sec-
ond and subsequent infusion in a course of therapy. Patient
and family satisfaction were also improved.461
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Background: Chemotherapy followed by ﬁlgrastim is the
most common strategy used to mobilize cells for high dose
chemotherapy and autologous stem cell transplantation.
Unfortunately, this method does not always lead to adequate
cell collection in heavily pretreated patients with relapsed
malignancies or if multiple transplants are required. Plerix-
afor is an agent that has been studied in adults and has been
shown to be safe and efﬁcacious in the mobilization of pe-
ripheral blood stem cells (PBSC). Plerixafor is hematopoietic
stem cell mobilizer which inhibits the CXCR4 chemokine
receptor and blocks binding of its cognate ligand, stromal
cell-derived factor-1-alpha (SDF-1-alpha) which results in
leukocytosis and elevations in circulating hematopoietic
progenitor cells. Despite its use in adults, little evidence ex-
ists to support its use in children. Here we report our ob-
servations of 11 children at Cincinnati Children’s Hospital
Medical Center (CCHMC) who received plerixafor tomobilize
PBSC.
